Patents by Inventor Jingwen SI

Jingwen SI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • gRNA targeting HPK1 and a method for editing HPK1 gene
    Patent number: 11786550
    Abstract: Provided is a gRNA targeting HPK1 and a method for editing HPK1 gene. The method can knock out the T cell HPK1 gene, enhance the T cell killing activity, increase the Th1 cytokine level of peripheral blood mononuclear cells, and knock out of the T cell HPK1 gene can also down-regulate the expression of PD-1 and TIM3 on the T cell surface and can inhibit the T cell depletion.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: October 17, 2023
    Assignee: Beijing Synthetic Vaccine Biosciences Co., Ltd
    Inventors: Xuebin Liao, Jingwen Si
  • A gRNA TARGETING HPK1 AND A METHOD FOR EDITING HPK1 GENE
    Publication number: 20220023340
    Abstract: Provided is a gRNA targeting HPK1 and a method for editing HPK1 gene. The method can knock out the T cell HPK1 gene, enhance the T cell killing activity, increase the Th1 cytokine level of peripheral blood mononuclear cells, and knock out of the T cell HPK1 gene can also down-regulate the expression of PD-1 and TIM3 on the T cell surface and can inhibit the T cell depletion.
    Type: Application
    Filed: September 20, 2018
    Publication date: January 27, 2022
    Inventors: Xuebin LIAO, Jingwen SI